Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: a meta-analysis.

IF 6.3 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Systematic Reviews Pub Date : 2025-05-09 DOI:10.1186/s13643-025-02847-7

Zhong Wu, Zongxin Zhang, Chao Gu

{"title":"Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: a meta-analysis.","authors":"Zhong Wu, Zongxin Zhang, Chao Gu","doi":"10.1186/s13643-025-02847-7","DOIUrl":null,"url":null,"abstract":"Background: Although the systemic inflammation response index (SIRI) is often associated with prognostic significance in esophageal cancer (EC) patients, the results continue to be conflicting. We focused on identifying SIRI's precise role in forecasting EC prognosis through performing this meta-analysis.Methods: This work searched PubMed, Web of Science, Embase, Cochrane Library, and CNKI till November 16, 2024, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for evaluating EC prognosis forecasting efficiency of SIRI. The inclusion criteria: (1) pathologic confirmation of EC; (2) those reporting associations of SIRI with EC survival outcomes; (3) those reporting HRs and 95% CIs; (4) those with an available cut-off value of SIRI; and (5) no restriction in language. The exclusion criteria: (1) case reports, reviews, meeting abstracts, comments and letters; (2) those enrolling duplicate cases; and (3) animal studies.Results: We enrolled six studies comprising 2176 cases into the present work. Based on our combined findings, elevated SIRI showed significant relation to dismal overall survival (OS) (HR = 1.43, 95%CI = 1.20-1.71, p < 0.001; I2 = 48.8%, p = 0.098) and shortened progression-free survival (PFS) (HR = 2.00, 95%CI = 1.35-2.98, p = 0.001; I2 = 0, p = 0.409) in EC. Moreover, high SIRI exhibited obvious relation to male gender (OR = 1.86, 95%CI = 1.07-3.22, p = 0.027; I2 = 69.4%, p = 0.020), TNM stage of III-IV (OR = 1.52, 95%CI = 1.18-1.94, p = 0.001; I2 = 24.3%, p = 0.265), T3-T4 stage (OR = 1.73, 95%CI = 1.12-2.69, p = 0.014; I2 = 61.0%, p = 0.053), and lymph node metastasis (OR = 1.29, 95%CI = 1.02-1.64, p = 0.036; I2 = 42.7%, p = 0.155). However, SIRI was not markedly related to age, tumor location, tumor differentiation, or smoking history.Conclusion: In summary, high SIRI is significantly related to dismal OS and shortened PFS of EC cases, together with advanced tumor stage, T3-T4 stage, and lymph node metastasis of EC. Due to some limitations, large prospective studies that utilize standardized threshold SIRI should be conducted to validate our results in the future.","PeriodicalId":22162,"journal":{"name":"Systematic Reviews","volume":"14 1","pages":"104"},"PeriodicalIF":6.3000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063246/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13643-025-02847-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Although the systemic inflammation response index (SIRI) is often associated with prognostic significance in esophageal cancer (EC) patients, the results continue to be conflicting. We focused on identifying SIRI's precise role in forecasting EC prognosis through performing this meta-analysis.

Methods: This work searched PubMed, Web of Science, Embase, Cochrane Library, and CNKI till November 16, 2024, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for evaluating EC prognosis forecasting efficiency of SIRI. The inclusion criteria: (1) pathologic confirmation of EC; (2) those reporting associations of SIRI with EC survival outcomes; (3) those reporting HRs and 95% CIs; (4) those with an available cut-off value of SIRI; and (5) no restriction in language. The exclusion criteria: (1) case reports, reviews, meeting abstracts, comments and letters; (2) those enrolling duplicate cases; and (3) animal studies.

Results: We enrolled six studies comprising 2176 cases into the present work. Based on our combined findings, elevated SIRI showed significant relation to dismal overall survival (OS) (HR = 1.43, 95%CI = 1.20-1.71, p < 0.001; I² = 48.8%, p = 0.098) and shortened progression-free survival (PFS) (HR = 2.00, 95%CI = 1.35-2.98, p = 0.001; I² = 0, p = 0.409) in EC. Moreover, high SIRI exhibited obvious relation to male gender (OR = 1.86, 95%CI = 1.07-3.22, p = 0.027; I² = 69.4%, p = 0.020), TNM stage of III-IV (OR = 1.52, 95%CI = 1.18-1.94, p = 0.001; I² = 24.3%, p = 0.265), T3-T4 stage (OR = 1.73, 95%CI = 1.12-2.69, p = 0.014; I² = 61.0%, p = 0.053), and lymph node metastasis (OR = 1.29, 95%CI = 1.02-1.64, p = 0.036; I² = 42.7%, p = 0.155). However, SIRI was not markedly related to age, tumor location, tumor differentiation, or smoking history.

Conclusion: In summary, high SIRI is significantly related to dismal OS and shortened PFS of EC cases, together with advanced tumor stage, T3-T4 stage, and lymph node metastasis of EC. Due to some limitations, large prospective studies that utilize standardized threshold SIRI should be conducted to validate our results in the future.

查看原文本刊更多论文

系统性炎症反应指数（SIRI）对食管癌患者预后和临床病理的影响：一项荟萃分析

背景：虽然系统性炎症反应指数（SIRI）通常与食管癌（EC）患者的预后意义相关，但结果仍然相互矛盾。通过进行meta分析，我们专注于确定SIRI在预测EC预后中的精确作用。方法：检索PubMed、Web of Science、Embase、Cochrane Library、CNKI至2024年11月16日，确定评价SIRI预测EC预后效率的汇总风险比（hr）和95%置信区间（ci）。纳入标准：(1)经病理证实的EC；(2)报告了SIRI与EC生存结局的关联；(3)报告hr和95% ci者；(4)具有可用SIRI截断值的；(5)语言不受限制。排除标准：(1)病例报告、综述、会议摘要、意见和信函；（二）招收重复病例的；(3)动物实验。结果：我们纳入了6项研究，共2176例。根据我们的综合研究结果，SIRI升高与总生存期（OS）降低（HR = 1.43, 95%CI = 1.20-1.71, p 2 = 48.8%, p = 0.098）和无进展生存期（PFS）缩短（HR = 2.00, 95%CI = 1.35-2.98, p = 0.001）显著相关；I2 = 0, p = 0.409)。此外，高SIRI与男性性别有显著相关(OR = 1.86, 95%CI = 1.07-3.22, p = 0.027；I2 = 69.4%, p = 0.020), TNM阶段iii iv (OR = 1.52, 95% ci -1.94 = 1.18, p = 0.001;I2 = 24.3%, p = 0.265), T3-T4阶段(OR = 1.73, 95% ci -2.69 = 1.12, p = 0.014;I2 = 61.0%, p = 0.053),与淋巴结转移(OR = 1.29, 95% ci -1.64 = 1.02, p = 0.036;I2 = 42.7%, p = 0.155)。然而，SIRI与年龄、肿瘤位置、肿瘤分化或吸烟史无关。结论：综上所述，高SIRI与EC患者OS下降、PFS缩短、肿瘤分期晚期、T3-T4期及淋巴结转移有显著关系。由于一些限制，应该进行使用标准化阈值SIRI的大型前瞻性研究，以在未来验证我们的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Systematic Reviews Medicine-Medicine (miscellaneous)

CiteScore

8.30

自引率

0.00%

发文量

241

审稿时长

11 weeks

期刊介绍： Systematic Reviews encompasses all aspects of the design, conduct and reporting of systematic reviews. The journal publishes high quality systematic review products including systematic review protocols, systematic reviews related to a very broad definition of health, rapid reviews, updates of already completed systematic reviews, and methods research related to the science of systematic reviews, such as decision modelling. At this time Systematic Reviews does not accept reviews of in vitro studies. The journal also aims to ensure that the results of all well-conducted systematic reviews are published, regardless of their outcome.